Evidence map›Paper›PMID 39652302›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2024

Regulation of AUF1 alternative splicing by hnRNPA1 and SRSF2 modulate the sensitivity of ovarian cancer cells to cisplatin.

Jia-Mei Wang, Ning Liu, Xue-Jing Wei, Fu-Ying Zhao, Chao Li, Hua-Qin Wang, Chuan Liu

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Jia-Mei Wang *National Clinical Research Center for Laboratory Medicine, Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, 110001, China.
Ning Liu *Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Xue-Jing WeiDepartment of Biochemistry and Molecular Biology, China Medical University, Shenyang, 110026, China.
Fu-Ying ZhaoDepartment of Biochemistry and Molecular Biology, China Medical University, Shenyang, 110026, China.
Chao LiDepartment of Biochemistry and Molecular Biology, China Medical University, Shenyang, 110026, China.
Hua-Qin WangDepartment of Biochemistry and Molecular Biology, China Medical University, Shenyang, 110026, China.
Chuan LiuDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110004, China. liuc@sj-hospital.org.

Funding

National Natural Science Foundation of China 82003100
6 · The paper itself

Abstract

purposeClarification of cisplatin resistance may provide new targets for therapy in cisplatin resistant ovarian cancer. The current study aims to explore involvement of isoforms of AU-rich element RNA-binding protein 1 (AUF1) in cisplatin resistance in ovarian cancer.

methodsThe cancer stem cell-like features were analyzed using colony formation assay, tumor sphere formation assay and nude mouse xenograft experiments. AUF1 isoforms expression was analyzed using immunoblotting, qRT-PCR, and immunohistochemistry. RIP and Biotin pulldown was used to analyze the interaction of SRSF2 and hnRNPA1 with AUF1 transcript. Transcriptome regulated by AUF1 isoforms was analyzed by RNA-seq.

resultsThe current study demonstrated differential expression of AUF1 isoforms in cisplatin sensitive and resistant ovarian cancer tissues and cells. P37 isoform promoted proliferation, while p45 isoform enhanced responsiveness of ovarian cancer cells to cisplatin. the clonal formation capacity of the cells, and the restoration of p45 expression reduced the capacity with cisplatin treatment. The competitive binding of phosphorylated hnRNPA1 and O-GlcNAc-modified SRSF2 on AUF1 exon 2 and exon 7 regulated the alternative splicing of AUF1.

conclusionThe competitive binding of phosphorylated hnRNPA1 and O-GlcNAc modified SRSF2 on exon 2 and exon 7 regulated the alternative splicing of AUF1 and subsequent isoform expression. P37 isoform played a "cancer promoter" role, p42 and p45, especially p45 played a "cancer suppressor" role in ovarian cancer. This study provides a new target for exploring the drug resistance mechanism of ovarian cancer.

Indexed as

Alternative SplicingCisplatinDrug Resistance, NeoplasmHeterogeneous Nuclear Ribonucleoprotein A1Mice, NudeOvarian NeoplasmsSerine-Arginine Splicing FactorsAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHeterogeneous-Nuclear Ribonucleoprotein Group A-BHumansMiceAntineoplastic AgentsCisplatinHeterogeneous Nuclear Ribonucleoprotein A1Heterogeneous-Nuclear Ribonucleoprotein Group A-BhnRNPA1 protein, humanProtein IsoformsSerine-Arginine Splicing FactorsSRSF2 protein, humanAlternative splicingAU-rich element RNA-binding protein 1 (AUF1)CisplatinOvarian cancer

Identifiers

PMID39652302
PMCPMC12974074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.